128 related articles for article (PubMed ID: 23106108)
1. Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.
Lotta LA; Degasperi E; Aghemo A; Ferrari B; Peyvandi F; Colombo M
Transfus Med; 2013 Feb; 23(1):66-68. PubMed ID: 23106108
[No Abstract] [Full Text] [Related]
2. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b.
Deutsch M; Manesis EK; Hadziyannis E; Vassilopoulos D; Archimandritis AJ
Scand J Gastroenterol; 2007 Mar; 42(3):408-9. PubMed ID: 17354123
[No Abstract] [Full Text] [Related]
3. [Thrombotic thrombocytopenic purpura mediated by an ADAMTS13-inhibitor related to a treatment with pegylated-interferon alpha-2a and ribavirine in a patient with chronic hepatitis C].
Lambot F; Hanson B; Sztern B
Presse Med; 2010 Nov; 39(11):1207-10. PubMed ID: 20609558
[No Abstract] [Full Text] [Related]
4. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C.
Kitano K; Gibo Y; Kamijo A; Furuta K; Oguchi S; Joshita S; Takahashi Y; Ishida F; Matsumoto M; Uemura M; Fujimura Y
Haematologica; 2006 Aug; 91(8 Suppl):ECR34. PubMed ID: 16923518
[TBL] [Abstract][Full Text] [Related]
5. Interferon-α is not elevated in idiopathic thrombotic thrombocytopenic purpura patients.
Watanaboonyongcharoen P; Whinna HC; Park YA
J Clin Apher; 2014 Dec; 29(6):336-8. PubMed ID: 24764259
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic thrombocytopenic purpura complicating interferon therapy in chronic C hepatitis.
Sallée M; Crétel E; Jean R; Chiche L; Bourlière M; Poullin P; Lefèvre P; Durand JM
Gastroenterol Clin Biol; 2008 Feb; 32(2):145-6. PubMed ID: 18496890
[No Abstract] [Full Text] [Related]
8. Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13.
Saeki T; Ito T; Youkou A; Ishiguro H; Sato N; Yamazaki H; Koike T; Kourakata H; Ferrari S; Scheiflinger F; Narita I
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1209-12. PubMed ID: 21523922
[No Abstract] [Full Text] [Related]
9. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital.
Sato T; Hanaoka R; Ohshima M; Miwa Y; Okazaki Y; Yajima N; Ishizashi H; Matsumoto M; Fujimura Y; Inokuma S
Clin Exp Rheumatol; 2006; 24(4):454-5. PubMed ID: 16956441
[No Abstract] [Full Text] [Related]
10. [Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].
Primo Vera J
Gastroenterol Hepatol; 2004 Feb; 27(2):69. PubMed ID: 14733882
[No Abstract] [Full Text] [Related]
11. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Hadziyannis SJ; Sevastianos V
Aliment Pharmacol Ther; 2013 Feb; 37(4):491. PubMed ID: 23336678
[No Abstract] [Full Text] [Related]
12. Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia.
Balkan II; Bozcan S; Yemisen M; Kutlubay Z; Ozaras R
Ann Hepatol; 2014; 13(6):843-4. PubMed ID: 25332274
[No Abstract] [Full Text] [Related]
13. [Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
An J; Qiao J; Ni W
Zhonghua Gan Zang Bing Za Zhi; 2014 Oct; 22(10):772-3. PubMed ID: 25558497
[No Abstract] [Full Text] [Related]
14. Thrombotic thrombocytopenic purpura and its diagnosis.
Veyradier A; Meyer D
J Thromb Haemost; 2005 Nov; 3(11):2420-7. PubMed ID: 15892859
[No Abstract] [Full Text] [Related]
15. The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report.
Lebano R; Rosato V; Masarone M; Romano M; Persico M
BMC Res Notes; 2014 Jan; 7():59. PubMed ID: 24457056
[TBL] [Abstract][Full Text] [Related]
16. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
17. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
18. Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
Cua IH; Kwan V; Henriquez M; Kench J; George J
Gut; 2006 Oct; 55(10):1521-2. PubMed ID: 16966706
[No Abstract] [Full Text] [Related]
19. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
Tsai HM
Kidney Int Suppl; 2009 Feb; (112):S11-4. PubMed ID: 19180123
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
Liu CH; Liang CC; Liu CJ; Tsai HB; Hung PH; Hsu SJ; Chen SI; Lin JW; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
Gut; 2009 Feb; 58(2):314-6. PubMed ID: 19136527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
